1. Home
  2. TRVG vs IFRX Comparison

TRVG vs IFRX Comparison

Compare TRVG & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

HOLD

Current Price

$5.45

Market Cap

375.4M

Sector

Technology

ML Signal

HOLD

Logo InflaRx N.V.

IFRX

InflaRx N.V.

HOLD

Current Price

$1.85

Market Cap

303.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVG
IFRX
Founded
2005
2007
Country
Germany
Germany
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
375.4M
303.4M
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
TRVG
IFRX
Price
$5.45
$1.85
Analyst Decision
Hold
Strong Buy
Analyst Count
6
4
Target Price
$3.95
$6.25
AVG Volume (30 Days)
119.5K
1.5M
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.59
N/A
Revenue Next Year
$8.42
N/A
P/E Ratio
$16.98
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$0.74
52 Week High
$5.70
$2.95

Technical Indicators

Market Signals
Indicator
TRVG
IFRX
Relative Strength Index (RSI) 64.47 41.44
Support Level $2.78 $0.87
Resistance Level $5.70 $1.94
Average True Range (ATR) 0.33 0.20
MACD -0.04 -0.03
Stochastic Oscillator 53.52 3.73

Price Performance

Historical Comparison
TRVG
IFRX

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About IFRX InflaRx N.V.

InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Share on Social Networks: